Innovation recognised at AMWC 2026
CMed Aesthetics received the “Most Disruptive Innovation” award within the Catalyst Finalist category at AMWC 2026, following participation in the Catalyst Pitch & Connect Stage on March 27.
The recognition highlighted our patented NTS® technology and its approach to sterilisation. It reflects the research and development at the heart of CMed Aesthetics and our commitment to safety, quality and scientific excellence.
Spotlight on innovation: NTS® technology
On March 27, our CEO and Founder, Carlo Michelini, together with Dr. Domenico Romano, aesthetic doctor and plastic surgeon, presented at the Open Stage of the congress.
The talk focused on our patented NTS® technology, a sterilisation solution designed to elevate safety and quality standards in aesthetic medicine. It was an opportunity to share our scientific approach and forward-looking vision with an international audience.
Discover CMed Aesthetics ANZ
Learn more about CMed Aesthetics ANZ, the Australian and New Zealand distributor of CMed Aesthetics products, and explore our BioReTherapy BioRePeelCl₃® Professional range and LUMINESCENS® clarifying and brightening solution.